Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A1

Michael D. Tarantino, Peter W. Collins, Charles R M Hay, A. D. Shapiro, Ralph A. Gruppo, Erik Berntorp, G. L. Bray, S. A. Tonetta, P. C. Schroth, A. D. Retzios, S. S. Rogy, M. G. Sensel, B. M. Ewenstein, Thomas Abshire, Wing Yen Wong, Jorgen Ingerslev, Amy Shapiro, Peter W. Marks, Roshni Kulkarni, Margaret V. RagniAnne Marie Hurlet-Jensen, Arthur Thompson, Paul Giangrande, Christine Lee, Pier Mannuccio Manucci, Claude Negrier, Jozef Vermylen, Joan Gill, Ingrid Pabinger, Claire Philipp, Rachelle Nuss, Donna Di Michele

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

The efficacy and safety of an advanced category recombinant antihaemophilic factor produced by a plasma- and albumin-free method (rAHF-PFM) was studied in 111 previously treated subjects with haemophilia A. The study comprised a randomized, double-blinded, crossover pharmacokinetic comparison of rAHF-PFM and RECOMBINATE rAHF (R-FVIII); prophylaxis (three to four times per week with 25-40 IU kg-1 rAHF-PFM) for at least 75 exposure days; and treatment of episodic haemorrhagic events. Median age was 18 years, 96% of subjects had baseline factor VIII -1 year-1) than subjects who were more adherent (4.4 episodes subject-1 year-1; P <0.03). One subject developed a low titre, non-persistent inhibitor (2.0 BU) after 26 exposure days. These data demonstrate that rAHF-PFM is bioequivalent to R-FVIII, and suggest that rAHF-PFM is efficacious and safe, without increased immunogenicity, for the treatment of haemophilia A.

Original languageEnglish
Pages (from-to)428-437
Number of pages10
JournalHaemophilia
Volume10
Issue number5
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Hemophilia A
Serum Albumin
Pharmacokinetics
Safety
Factor VIII
Therapeutics
human F8 protein

Keywords

  • Factor VIII
  • Haemophilia A
  • Recombinant antihaemophilic factor plasma-free method
  • Recombinant factor VIII

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method : Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A1. / Tarantino, Michael D.; Collins, Peter W.; Hay, Charles R M; Shapiro, A. D.; Gruppo, Ralph A.; Berntorp, Erik; Bray, G. L.; Tonetta, S. A.; Schroth, P. C.; Retzios, A. D.; Rogy, S. S.; Sensel, M. G.; Ewenstein, B. M.; Abshire, Thomas; Wong, Wing Yen; Ingerslev, Jorgen; Shapiro, Amy; Marks, Peter W.; Kulkarni, Roshni; Ragni, Margaret V.; Hurlet-Jensen, Anne Marie; Thompson, Arthur; Giangrande, Paul; Lee, Christine; Manucci, Pier Mannuccio; Negrier, Claude; Vermylen, Jozef; Gill, Joan; Pabinger, Ingrid; Philipp, Claire; Nuss, Rachelle; Di Michele, Donna.

In: Haemophilia, Vol. 10, No. 5, 09.2004, p. 428-437.

Research output: Contribution to journalArticle

Tarantino, MD, Collins, PW, Hay, CRM, Shapiro, AD, Gruppo, RA, Berntorp, E, Bray, GL, Tonetta, SA, Schroth, PC, Retzios, AD, Rogy, SS, Sensel, MG, Ewenstein, BM, Abshire, T, Wong, WY, Ingerslev, J, Shapiro, A, Marks, PW, Kulkarni, R, Ragni, MV, Hurlet-Jensen, AM, Thompson, A, Giangrande, P, Lee, C, Manucci, PM, Negrier, C, Vermylen, J, Gill, J, Pabinger, I, Philipp, C, Nuss, R & Di Michele, D 2004, 'Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A1', Haemophilia, vol. 10, no. 5, pp. 428-437. https://doi.org/10.1111/j.1365-2516.2004.00932.x
Tarantino, Michael D. ; Collins, Peter W. ; Hay, Charles R M ; Shapiro, A. D. ; Gruppo, Ralph A. ; Berntorp, Erik ; Bray, G. L. ; Tonetta, S. A. ; Schroth, P. C. ; Retzios, A. D. ; Rogy, S. S. ; Sensel, M. G. ; Ewenstein, B. M. ; Abshire, Thomas ; Wong, Wing Yen ; Ingerslev, Jorgen ; Shapiro, Amy ; Marks, Peter W. ; Kulkarni, Roshni ; Ragni, Margaret V. ; Hurlet-Jensen, Anne Marie ; Thompson, Arthur ; Giangrande, Paul ; Lee, Christine ; Manucci, Pier Mannuccio ; Negrier, Claude ; Vermylen, Jozef ; Gill, Joan ; Pabinger, Ingrid ; Philipp, Claire ; Nuss, Rachelle ; Di Michele, Donna. / Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method : Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A1. In: Haemophilia. 2004 ; Vol. 10, No. 5. pp. 428-437.
@article{2126ca9c46a44921b94aa1e3f3a5d945,
title = "Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A1",
abstract = "The efficacy and safety of an advanced category recombinant antihaemophilic factor produced by a plasma- and albumin-free method (rAHF-PFM) was studied in 111 previously treated subjects with haemophilia A. The study comprised a randomized, double-blinded, crossover pharmacokinetic comparison of rAHF-PFM and RECOMBINATE rAHF (R-FVIII); prophylaxis (three to four times per week with 25-40 IU kg-1 rAHF-PFM) for at least 75 exposure days; and treatment of episodic haemorrhagic events. Median age was 18 years, 96{\%} of subjects had baseline factor VIII -1 year-1) than subjects who were more adherent (4.4 episodes subject-1 year-1; P <0.03). One subject developed a low titre, non-persistent inhibitor (2.0 BU) after 26 exposure days. These data demonstrate that rAHF-PFM is bioequivalent to R-FVIII, and suggest that rAHF-PFM is efficacious and safe, without increased immunogenicity, for the treatment of haemophilia A.",
keywords = "Factor VIII, Haemophilia A, Recombinant antihaemophilic factor plasma-free method, Recombinant factor VIII",
author = "Tarantino, {Michael D.} and Collins, {Peter W.} and Hay, {Charles R M} and Shapiro, {A. D.} and Gruppo, {Ralph A.} and Erik Berntorp and Bray, {G. L.} and Tonetta, {S. A.} and Schroth, {P. C.} and Retzios, {A. D.} and Rogy, {S. S.} and Sensel, {M. G.} and Ewenstein, {B. M.} and Thomas Abshire and Wong, {Wing Yen} and Jorgen Ingerslev and Amy Shapiro and Marks, {Peter W.} and Roshni Kulkarni and Ragni, {Margaret V.} and Hurlet-Jensen, {Anne Marie} and Arthur Thompson and Paul Giangrande and Christine Lee and Manucci, {Pier Mannuccio} and Claude Negrier and Jozef Vermylen and Joan Gill and Ingrid Pabinger and Claire Philipp and Rachelle Nuss and {Di Michele}, Donna",
year = "2004",
month = "9",
doi = "10.1111/j.1365-2516.2004.00932.x",
language = "English",
volume = "10",
pages = "428--437",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method

T2 - Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A1

AU - Tarantino, Michael D.

AU - Collins, Peter W.

AU - Hay, Charles R M

AU - Shapiro, A. D.

AU - Gruppo, Ralph A.

AU - Berntorp, Erik

AU - Bray, G. L.

AU - Tonetta, S. A.

AU - Schroth, P. C.

AU - Retzios, A. D.

AU - Rogy, S. S.

AU - Sensel, M. G.

AU - Ewenstein, B. M.

AU - Abshire, Thomas

AU - Wong, Wing Yen

AU - Ingerslev, Jorgen

AU - Shapiro, Amy

AU - Marks, Peter W.

AU - Kulkarni, Roshni

AU - Ragni, Margaret V.

AU - Hurlet-Jensen, Anne Marie

AU - Thompson, Arthur

AU - Giangrande, Paul

AU - Lee, Christine

AU - Manucci, Pier Mannuccio

AU - Negrier, Claude

AU - Vermylen, Jozef

AU - Gill, Joan

AU - Pabinger, Ingrid

AU - Philipp, Claire

AU - Nuss, Rachelle

AU - Di Michele, Donna

PY - 2004/9

Y1 - 2004/9

N2 - The efficacy and safety of an advanced category recombinant antihaemophilic factor produced by a plasma- and albumin-free method (rAHF-PFM) was studied in 111 previously treated subjects with haemophilia A. The study comprised a randomized, double-blinded, crossover pharmacokinetic comparison of rAHF-PFM and RECOMBINATE rAHF (R-FVIII); prophylaxis (three to four times per week with 25-40 IU kg-1 rAHF-PFM) for at least 75 exposure days; and treatment of episodic haemorrhagic events. Median age was 18 years, 96% of subjects had baseline factor VIII -1 year-1) than subjects who were more adherent (4.4 episodes subject-1 year-1; P <0.03). One subject developed a low titre, non-persistent inhibitor (2.0 BU) after 26 exposure days. These data demonstrate that rAHF-PFM is bioequivalent to R-FVIII, and suggest that rAHF-PFM is efficacious and safe, without increased immunogenicity, for the treatment of haemophilia A.

AB - The efficacy and safety of an advanced category recombinant antihaemophilic factor produced by a plasma- and albumin-free method (rAHF-PFM) was studied in 111 previously treated subjects with haemophilia A. The study comprised a randomized, double-blinded, crossover pharmacokinetic comparison of rAHF-PFM and RECOMBINATE rAHF (R-FVIII); prophylaxis (three to four times per week with 25-40 IU kg-1 rAHF-PFM) for at least 75 exposure days; and treatment of episodic haemorrhagic events. Median age was 18 years, 96% of subjects had baseline factor VIII -1 year-1) than subjects who were more adherent (4.4 episodes subject-1 year-1; P <0.03). One subject developed a low titre, non-persistent inhibitor (2.0 BU) after 26 exposure days. These data demonstrate that rAHF-PFM is bioequivalent to R-FVIII, and suggest that rAHF-PFM is efficacious and safe, without increased immunogenicity, for the treatment of haemophilia A.

KW - Factor VIII

KW - Haemophilia A

KW - Recombinant antihaemophilic factor plasma-free method

KW - Recombinant factor VIII

UR - http://www.scopus.com/inward/record.url?scp=4944263724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4944263724&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2004.00932.x

DO - 10.1111/j.1365-2516.2004.00932.x

M3 - Article

C2 - 15357767

AN - SCOPUS:4944263724

VL - 10

SP - 428

EP - 437

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 5

ER -